Qlt Inc (QLTI) 5.92 $QLTI
QLT Has Returned 13.5% Since SmarTrend Recommendation (QLTI)
Comtex SmarTrend(R) - Wed Apr 09, 9:18AM CDT
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 4 months, QLT has returned 13.51% as of today's recent price of $6.26.
QLT Inc. (QLTI) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 6:56AM CDT
QLT Inc. (QLTI) is now in Oversold Territory
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Uptrend Call Working As QLT Stock Rises 15.3% (QLTI)
Comtex SmarTrend(R) - Fri Feb 28, 11:14AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 3 months, QLT has returned 15.32% as of today's recent price of $6.36.
QLT Announces Fourth Quarter and Year End 2013 Results
GlobeNewswire - Fri Feb 28, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the fourth quarter and year ended December 31, 2013. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLT Announces Positive Preliminary Results From Phase 1b Retreatment Trial of QLT091001 in Subjects With Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65
GlobeNewswire - Thu Feb 27, 6:45AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced positive preliminary results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT).
QLT Shares Up 18.2% Since SmarTrend's Buy Recommendation (QLTI)
Comtex SmarTrend(R) - Fri Feb 21, 9:55AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 3 months, QLT has returned 18.22% as of today's recent price of $6.52.
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
18.8% Return Seen to Date on SmarTrend QLT Call (QLTI)
Comtex SmarTrend(R) - Thu Feb 06, 5:09PM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 18.77% as of today's recent price of $6.55.
27.3% Return Seen to Date on SmarTrend QLT Call (QLTI)
Comtex SmarTrend(R) - Thu Jan 30, 11:03AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 27.29% as of today's recent price of $7.02.
Latest Retinitis Pigmentosa (Retinitis) Pipeline Review
M2 - Tue Jan 28, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjq6dr/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sangamo BioSciences, Inc. - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - Amarantus Bioscience Holdings, Inc. - ProRetina Therapeutics, S.L - RetroSense Therapeutics, LLC - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/cjq6dr/retinitis
Uptrend Call Working As QLT Stock Rises 23.1% (QLTI)
Comtex SmarTrend(R) - Thu Jan 23, 9:43AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 23.12% as of today's recent price of $6.79.
Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2013
M2 - Fri Jan 17, 9:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/97z3bk/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2013" report to their offering. Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2013 provides data on the Retinitis Pigmentosa (Retinitis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Retinitis Pigmentosa (Retinitis). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Retinitis Pigmentosa (Retinitis). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials - QLT Inc. - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Oxford BioMedica plc - Johnson & Johnson - Isis Pharmaceuticals, Inc. - DNAVEC Corporation - Daewoong Pharmaceutical Co., Ltd. - BioDiem Ltd - Allergan, Inc. Clinical Trial Overview of Top Institutes / Government - National Eye Institute - The Sheba Medical Center - Kyushu University - National Center for Research Resources - Southwest Hospital, China - University of Sao Paulo - Columbia University - Third Military Medical University - Tehran University of Medical Sciences - Chiba University Hospital For more information visit http://www.researchandmarkets.com/research/97z3bk/retinitis
Shares of QLTI Up 19.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 16, 9:20AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 19.49% as of today's recent price of $6.59.
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 19, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
QLT Announces First Patient Dosed in Phase IIa Proof-of-Concept Trial for QLT091001 in Impaired Dark Adaptation
GlobeNewswire - Mon Dec 09, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that the first patient has been dosed in the Company's Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation (IDA), a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights.
QLT Down 29.9% Since SmarTrend Downtrend Call (QLTI)
Comtex SmarTrend(R) - Wed Nov 27, 4:45PM CST
SmarTrend identified a Downtrend for QLT (NASDAQ:QLTI) on May 3rd, 2013 at $7.77. In approximately 7 months, QLT has returned 29.94% as of today's recent price of $5.44.
QLT Has Returned 13.5% Since SmarTrend Recommendation (QLTI)
Comtex SmarTrend(R) - Wed Apr 09, 9:18AM CDT
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 4 months, QLT has returned 13.51% as of today's recent price of $6.26.
QLT Inc. (QLTI) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 6:56AM CDT
QLT Inc. (QLTI) is now in Oversold Territory
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Uptrend Call Working As QLT Stock Rises 15.3% (QLTI)
Comtex SmarTrend(R) - Fri Feb 28, 11:14AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 3 months, QLT has returned 15.32% as of today's recent price of $6.36.
QLT Announces Fourth Quarter and Year End 2013 Results
GlobeNewswire - Fri Feb 28, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the fourth quarter and year ended December 31, 2013. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP. QLT Announces Positive Preliminary Results From Phase 1b Retreatment Trial of QLT091001 in Subjects With Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65
GlobeNewswire - Thu Feb 27, 6:45AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced positive preliminary results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT). QLT Shares Up 18.2% Since SmarTrend's Buy Recommendation (QLTI)
Comtex SmarTrend(R) - Fri Feb 21, 9:55AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 3 months, QLT has returned 18.22% as of today's recent price of $6.52.
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
18.8% Return Seen to Date on SmarTrend QLT Call (QLTI)
Comtex SmarTrend(R) - Thu Feb 06, 5:09PM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 18.77% as of today's recent price of $6.55.
27.3% Return Seen to Date on SmarTrend QLT Call (QLTI)
Comtex SmarTrend(R) - Thu Jan 30, 11:03AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 27.29% as of today's recent price of $7.02.
Latest Retinitis Pigmentosa (Retinitis) Pipeline Review
M2 - Tue Jan 28, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjq6dr/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sangamo BioSciences, Inc. - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - Amarantus Bioscience Holdings, Inc. - ProRetina Therapeutics, S.L - RetroSense Therapeutics, LLC - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/cjq6dr/retinitis
Uptrend Call Working As QLT Stock Rises 23.1% (QLTI)
Comtex SmarTrend(R) - Thu Jan 23, 9:43AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 23.12% as of today's recent price of $6.79.
Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2013
M2 - Fri Jan 17, 9:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/97z3bk/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2013" report to their offering. Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2013 provides data on the Retinitis Pigmentosa (Retinitis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Retinitis Pigmentosa (Retinitis). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Retinitis Pigmentosa (Retinitis). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials - QLT Inc. - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Oxford BioMedica plc - Johnson & Johnson - Isis Pharmaceuticals, Inc. - DNAVEC Corporation - Daewoong Pharmaceutical Co., Ltd. - BioDiem Ltd - Allergan, Inc. Clinical Trial Overview of Top Institutes / Government - National Eye Institute - The Sheba Medical Center - Kyushu University - National Center for Research Resources - Southwest Hospital, China - University of Sao Paulo - Columbia University - Third Military Medical University - Tehran University of Medical Sciences - Chiba University Hospital For more information visit http://www.researchandmarkets.com/research/97z3bk/retinitis
Shares of QLTI Up 19.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 16, 9:20AM CST
SmarTrend identified an Uptrend for QLT (NASDAQ:QLTI) on November 29th, 2013 at $5.52. In approximately 2 months, QLT has returned 19.49% as of today's recent price of $6.59.
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 19, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
QLT Announces First Patient Dosed in Phase IIa Proof-of-Concept Trial for QLT091001 in Impaired Dark Adaptation
GlobeNewswire - Mon Dec 09, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that the first patient has been dosed in the Company's Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation (IDA), a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights. QLT Down 29.9% Since SmarTrend Downtrend Call (QLTI)
Comtex SmarTrend(R) - Wed Nov 27, 4:45PM CST
SmarTrend identified a Downtrend for QLT (NASDAQ:QLTI) on May 3rd, 2013 at $7.77. In approximately 7 months, QLT has returned 29.94% as of today's recent price of $5.44.
